<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2023-16-4-141-146</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-1368</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FOR OPHTHALMOLOGY PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Применение нового противоаллергического препарата Эпинепта® в терапии сезонного аллергического конъюнктивита. Клинические случаи</article-title><trans-title-group xml:lang="en"><trans-title>Using a new antiallergic drug Epinepta® in the treatment of seasonal allergic conjunctivitis. Clinical cases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яни</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yani</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Владимировна Яни — канд. мед. наук, руководитель отдела инфекционных и аллергических заболеваний глаз</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062, Россия</p></bio><bio xml:lang="en"><p>Elena V. Yani — Cand. of Med. Sci, head of the department of infectious and allergic eye diseases</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia</p></bio><email xlink:type="simple">e_yani@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>12</month><year>2023</year></pub-date><volume>16</volume><issue>4</issue><fpage>141</fpage><lpage>146</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яни Е.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Яни Е.В.</copyright-holder><copyright-holder xml:lang="en">Yani E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/1368">https://roj.igb.ru/jour/article/view/1368</self-uri><abstract><p>Цель работы — изучение результатов применения нового противоаллергического препарата Эпинепта® в терапии сезонного аллергического конъюнктивита на материале клинических случаев.</p><sec><title>Материал и методы</title><p>Материал и методы. Пациенты (37 человек: 22 мужчин и 15 женщин) с аллергическим конъюнктивитом находились под наблюдением в период весеннего обострения: с середины марта по конец июня. Четко фиксировались показатели динамики субъективных жалоб, длительности лечения, клинической эффективности, легкости отмены препарата при нормализации состояния глазной поверхности.</p></sec><sec><title>Результаты</title><p>Результаты. Выделены четыре группы пациентов в зависимости от характера течения заболевания, клинических проявлений и ответа на терапию эпинастином. В качестве иллюстрации представлен разбор наиболее яркого клинического случая в каждой группе.</p></sec><sec><title>Заключение</title><p>Заключение. Использование в данных клинических случаях инстилляций эпинастина позволило добиться быстрого и стойкого уменьшения зуда, дискомфорта в глазах, а также нормализации клинического состояния конъюнктивы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to evaluate the effect of a new antiallergic drug epinastine in the treatment of seasonal conjunctivitis as manifested in clinical cases.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 37 people (22 men and 15 women) were observed during spring exacerbation of the allergic conjunctivitis, from mid-March to the end of June. Indicators of the dynamics of subjective complaints, duration of treatment, clinical effectiveness, were thoroughly recorded; we also assessed how easy it was to stop using the treatment when the condition of the ocular surface returned to normal.</p></sec><sec><title>Results</title><p>Results. We identified four groups of patients depending on the course of the disease, clinical manifestations, and response to epinastine therapy. For each group, we analyze a most informative clinical case.</p></sec><sec><title>Conclusions</title><p>Conclusions. In all of the cases, epinastine instillations brought about a quick and stable reduction of itching and eye discomfort, as well as normalization of the clinical condition of the conjunctiva.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сезонный аллергический конъюнктивит</kwd><kwd>эпинастин</kwd><kwd>эпинепта</kwd></kwd-group><kwd-group xml:lang="en"><kwd>seasonal allergic conjunctivitis</kwd><kwd>epinastine</kwd><kwd>Epinepta</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Терехова Е.П. Аллергический конъюнктивит: учебное пособие. ГБОУ ДПО «Российская медицинская академия последипломного образования». Москва: ГБОУ ДПО РМАПО, 2014.</mixed-citation><mixed-citation xml:lang="en">Terekhova E.P. Allergic conjunctivitis: textbook. GBOU DPO “Russian Medical Academy of Postgraduate Education”. Moscow: GBOU DPO RMAPO, 2014 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В., Вахова Е.С. Заболевания конъюнктивы. Национальное руководство по офтальмологии. ГЭОТАР-Медиа; 2017.</mixed-citation><mixed-citation xml:lang="en">Neroev V.V., Vakhova E.S. Diseases of the conjunctiva. National Guide for Ophthalmology. GEOTAR-Media, 2017 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tasaka K, Akagi M, Izushi K, Aoki I. Antiallergic effect of epinastine: the elucidation of the mechanism. Pharmacometrics. 1990; 39: 365–73.</mixed-citation><mixed-citation xml:lang="en">Tasaka K, Akagi M, Izushi K, Aoki I. Antiallergic effect of epinastine: the elucidation of the mechanism. Pharmacometrics. 1990; 39: 365–73.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fujishima H, Ohashi Y, Takamura E. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. Ann Allergy Asthma Immunol. 2014; 113: 476–81. https://doi.org/10.1016/j.anai.2014.07.007</mixed-citation><mixed-citation xml:lang="en">Fujishima H, Ohashi Y, Takamura E. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. Ann Allergy Asthma Immunol. 2014; 113: 476–81. https://doi.org/10.1016/j.anai.2014.07.007</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci. 2001 Feb; 42 (2): 321–7. PMID: 11157861.</mixed-citation><mixed-citation xml:lang="en">Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci. 2001 Feb; 42 (2): 321–7. PMID: 11157861.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005; 65 (2): 215–28. doi: 10.2165/00003495-200565020-00004</mixed-citation><mixed-citation xml:lang="en">Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005; 65 (2): 215–28. doi: 10.2165/00003495-200565020-00004</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006 Dec; 32 (6): 272–6. doi: 10.1097/01.icl.0000224360.10319.b1</mixed-citation><mixed-citation xml:lang="en">Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006 Dec; 32 (6): 272–6. doi: 10.1097/01.icl.0000224360.10319.b1</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wolff SC, Brubaker K, Navratil T, et al. Evaluation of muscarinic receptor antagonism by antihistamines. The Journal of Allergy and Clinical Immunology. 2007; 119 (1): S153. doi: https://doi.org/10.1016/j.jaci.2006.11.535</mixed-citation><mixed-citation xml:lang="en">Wolff SC, Brubaker K, Navratil T, et al. Evaluation of muscarinic receptor antagonism by antihistamines. The Journal of Allergy and Clinical Immunology. 2007; 119 (1): S153. doi: https://doi.org/10.1016/j.jaci.2006.11.535</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
